increased glutathione levels gliomas autophagy

increased glutathione levels gliomas autophagy Frontiers Macroautophagy/autophagy promotes resistance to KRASG12D-targeted

Name: increased glutathione levels gliomas autophagy Frontiers Macroautophagy/autophagy promotes resistance to KRASG12D-targeted
Brand: lagence-mr.com
SKU: 14762794494
Price: 27.15 USD
Availability: InStock
Rating: 4.2916 (22 reviews)

Macroautophagy autophagy promotes resistance to KRASG12D targeted therapy through glutathione synthesis ScienceDirect Frontiers Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge Study proposes a new strategy to intervene glutathione metabolism in the treatment of glioma Creative Peptides Blog Frontiers Beclin 1: a therapeutic target at the intersection of autophagy, immunotherapy, and cancer treatment Oncology Letters

SKU: 14762794494 · From lagence-mr.com

4.3

USD27.15 USD70.15

Pay in 4 interest-free payments of $6.79 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Oct 30 - Nov 4

Description

doi: 10.1007/s00383-002-0871-7

Due to their specific targeting capabilities, peptides are the way of the future, and many other types of peptides are under investigation for many conditions, including for organ functions, cancers, neurological injuries, and cognitive functions (e.g., semax and selank for cognition, kisspeptin for cancers, NVG-291 for spinal cord injury, P021 for Alzheimer's dementia, BIIB080 for Alzheimer's disease (actually an anti-sense nucleotide or ASO), and many others (154) (155) (156) (157) (158) (159) (160) (161) (162)

Furthermore, the combination of GDIL inhibition and platinum leads to delayed resistance, suggesting the functionality and specificity of GDIL as a therapeutic target